VX1

VERTEX PHARMAC. DL-,01

Stock XETRA – Stock Market Prices, News & Analysis

Vertex Pharmaceuticals est une société biopharmaceutique américaine spécialisée dans la recherche et le développement de traitements innovants pour les maladies graves, notamment la fibrose kystique.

€ 359.45

0.75 %

Healthcare & Biotech Healthcare & Biotech News United States

VERTEX PHARMAC. DL-,01

€ 359.45

0.75 %

VX1

Biopharmaceutique Recherche médicale Fibrose kystique Thérapies innovantes Pharmacie

Healthcare & Biotech Healthcare & Biotech News United States

Price history of VERTEX PHARMAC. DL-,01

Performance & Momentum

6 Months 1.38 %

1 Year 15.19 %

3 Years 22.41 %

5 Years –

Momentum

Unlock this indicator

Strategic Analysis

VERTEX PHARMAC. DL-,01 • 2026

Vertex Pharmaceuticals is positioned as a leader in U.S. biopharma, specializing in innovative therapies for serious diseases, with a strong foothold in cystic fibrosis. Its model is based on intensive R&D focused on high-value treatments, giving it a competitive advantage in a niche segment with high technological barriers.

Strengths

Recognized expertise and a focused portfolio in cystic fibrosis and rare diseases with strong potential
Sustained innovation capability thanks to significant R&D investment and a strategy centered on differentiated therapies
Strong growth track record over the medium and long term, enhancing its financial credibility and attractiveness

Weaknesses

Significant dependence on a limited number of flagship products, exposing the company to targeted market risks
Recent volatility in annual performance, which could reflect regulatory or commercial uncertainties

Momentum

The current moderate momentum reflects a rebound after a recent correction, indicating valuation upside that investors are reassessing. This dynamic suggests stabilization, with renewed interest in its pipeline and therapeutic advances.

Ask our AI about VERTEX PHARMAC. DL-,01

Analysis performed 1 month ago